Roflumilast 500 mcg Tablets – Trusted Respiratory Therapy Solution
Roflumilast 500 mcg Tablets are prescribed for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of frequent exacerbations. This phosphodiesterase-4 (PDE4) inhibitor helps reduce inflammation in the lungs, supporting improved respiratory function and reducing COPD flare-ups.
Cordium Pharmaceuticals provides high-quality Roflumilast 500 mcg Tablets for global pharmaceutical supply, hospital procurement, pharmacy distribution, and healthcare programs.
Composition
Each Film-Coated Tablet Contains:
Roflumilast IP/USP – 500 mcg
Excipients – q.s.
Suitable pharmaceutical-grade formulation for oral administration.
Therapeutic Category
Respiratory Medicine
Phosphodiesterase-4 (PDE4) Inhibitor
Anti-inflammatory Respiratory Agent
COPD Maintenance Therapy
Treatment Applications
Roflumilast 500 mcg Tablets are indicated for:
1. Severe COPD Management
Helps reduce airway inflammation and improves lung function in patients with severe COPD.
2. Chronic Bronchitis Associated COPD
Used in patients suffering from chronic bronchitis with persistent respiratory symptoms.
3. Prevention of COPD Exacerbations
Reduces the frequency and severity of COPD flare-ups requiring hospitalization or emergency treatment.
4. Long-Term Respiratory Support
Supports ongoing respiratory disease management when used alongside bronchodilator therapy.
5. Improved Quality of Life
Helps patients maintain better breathing capacity and daily activity levels.
Recommended Dosage
Typical Adult Dose: One tablet (500 mcg) once daily.
Tablets should be taken at the same time each day.
Dosage should always be determined by a qualified healthcare professional.
Not intended for immediate relief of acute bronchospasm.
Storage Instructions
Store below 25°C.
Protect from moisture and direct sunlight.
Keep tablets in original packaging.
Keep out of reach of children.
Do not use after the expiry date printed on the pack.
Benefits of Roflumilast 500 mcg Tablets
✔ Reduces COPD exacerbations
✔ Controls airway inflammation
✔ Supports long-term respiratory health
✔ Improves breathing efficiency
✔ Complements bronchodilator treatment
✔ Suitable for chronic respiratory disease management
South Africa Respiratory Healthcare Market
South Africa continues to experience significant demand for respiratory therapies due to smoking-related lung diseases, environmental pollution, occupational respiratory disorders, and chronic pulmonary conditions.
High-Demand Provinces for Respiratory Products in South Africa
Gauteng
Major healthcare facilities and respiratory specialists drive strong demand for COPD and asthma medications.
Western Cape
High prevalence of chronic respiratory conditions and advanced healthcare infrastructure.
KwaZulu-Natal
Growing requirement for respiratory medicines across public and private healthcare sectors.
Eastern Cape
Increasing demand for chronic pulmonary disease treatment solutions.
Free State
Expanding access to respiratory healthcare services and pharmaceutical supply.
Limpopo
Growing patient population requiring COPD maintenance therapies.
Mpumalanga
Industrial and mining activities contribute to respiratory disease management needs.
North West
Consistent demand for pulmonary and respiratory care products.
Northern Cape
Healthcare providers increasingly focusing on chronic respiratory disease treatment.
Global Pharmaceutical Supply Partner
Cordium Pharmaceuticals supports international pharmaceutical buyers, hospitals, distributors, pharmacies, wholesalers, and healthcare procurement agencies with reliable respiratory product exports and documentation support.
Contact for Business Enquiries
Cordium Pharmaceuticals
📱 WhatsApp: +91-9405117673
📧 Email: info@cordiumpharma.com
Roflumilast 500 mcg Tablets are prescribed for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of frequent exacerbations. This phosphodiesterase-4 (PDE4) inhibitor helps reduce inflammation in the lungs, supporting improved respiratory function and reducing COPD flare-ups.
Cordium Pharmaceuticals provides high-quality Roflumilast 500 mcg Tablets for global pharmaceutical supply, hospital procurement, pharmacy distribution, and healthcare programs.
Composition
Each Film-Coated Tablet Contains:
Roflumilast IP/USP – 500 mcg
Excipients – q.s.
Suitable pharmaceutical-grade formulation for oral administration.
Therapeutic Category
Respiratory Medicine
Phosphodiesterase-4 (PDE4) Inhibitor
Anti-inflammatory Respiratory Agent
COPD Maintenance Therapy
Treatment Applications
Roflumilast 500 mcg Tablets are indicated for:
1. Severe COPD Management
Helps reduce airway inflammation and improves lung function in patients with severe COPD.
2. Chronic Bronchitis Associated COPD
Used in patients suffering from chronic bronchitis with persistent respiratory symptoms.
3. Prevention of COPD Exacerbations
Reduces the frequency and severity of COPD flare-ups requiring hospitalization or emergency treatment.
4. Long-Term Respiratory Support
Supports ongoing respiratory disease management when used alongside bronchodilator therapy.
5. Improved Quality of Life
Helps patients maintain better breathing capacity and daily activity levels.
Recommended Dosage
Typical Adult Dose: One tablet (500 mcg) once daily.
Tablets should be taken at the same time each day.
Dosage should always be determined by a qualified healthcare professional.
Not intended for immediate relief of acute bronchospasm.
Storage Instructions
Store below 25°C.
Protect from moisture and direct sunlight.
Keep tablets in original packaging.
Keep out of reach of children.
Do not use after the expiry date printed on the pack.
Benefits of Roflumilast 500 mcg Tablets
✔ Reduces COPD exacerbations
✔ Controls airway inflammation
✔ Supports long-term respiratory health
✔ Improves breathing efficiency
✔ Complements bronchodilator treatment
✔ Suitable for chronic respiratory disease management
South Africa Respiratory Healthcare Market
South Africa continues to experience significant demand for respiratory therapies due to smoking-related lung diseases, environmental pollution, occupational respiratory disorders, and chronic pulmonary conditions.
High-Demand Provinces for Respiratory Products in South Africa
Gauteng
Major healthcare facilities and respiratory specialists drive strong demand for COPD and asthma medications.
Western Cape
High prevalence of chronic respiratory conditions and advanced healthcare infrastructure.
KwaZulu-Natal
Growing requirement for respiratory medicines across public and private healthcare sectors.
Eastern Cape
Increasing demand for chronic pulmonary disease treatment solutions.
Free State
Expanding access to respiratory healthcare services and pharmaceutical supply.
Limpopo
Growing patient population requiring COPD maintenance therapies.
Mpumalanga
Industrial and mining activities contribute to respiratory disease management needs.
North West
Consistent demand for pulmonary and respiratory care products.
Northern Cape
Healthcare providers increasingly focusing on chronic respiratory disease treatment.
Global Pharmaceutical Supply Partner
Cordium Pharmaceuticals supports international pharmaceutical buyers, hospitals, distributors, pharmacies, wholesalers, and healthcare procurement agencies with reliable respiratory product exports and documentation support.
Contact for Business Enquiries
Cordium Pharmaceuticals
📱 WhatsApp: +91-9405117673
📧 Email: info@cordiumpharma.com
Keywords
